4.7 Article

Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 79, 期 13, 页码 1223-1235

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2022.01.037

关键词

cardiogenic shock; coronary artery bypass grafting; mechanical circulatory support; myocardial infarction; percutaneous coronary intervention; peripheral artery disease

资金

  1. National Institutes of Health (NIH) [T32HL007208]
  2. Medtronic
  3. Boston Scientific
  4. Abbott Vascular
  5. Abiomed
  6. CSI
  7. CathWorks
  8. Siemens
  9. Philips
  10. ReCor Medical
  11. TriReme Medical
  12. SurModics
  13. Shockwave Medical
  14. NIH
  15. Intact Vascular
  16. AstraZeneca
  17. National Heart, Lung, and Blood Institute [R01HL136708]
  18. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology
  19. NIH/NHLBI [K23HL150290]
  20. Food & Drug Administration
  21. Harvard Medical School's Shore Faculty Development Award
  22. Bard
  23. Cook Medical
  24. Laminate Medical

向作者/读者索取更多资源

This study found that PAD was associated with worse limb outcomes and survival among patients with AMI and CS. Compared to those without PAD, patients with PAD had higher risks of in-hospital mortality, amputation, and out-of-hospital mortality.
BACKGROUND Mortality rates for patients presenting with acute myocardial infarction (AMI) and cardiogenic shock (CS) remain high despite advances in revascularization strategies and mechanical circulatory support (MCS) devices. OBJECTIVES This study sought to elucidate the association between comorbid lower extremity peripheral artery disease (PAD) and outcomes in CS and AMI. METHODS PAD status was defined in Medicare beneficiaries hospitalized with CS and AMI from October 1, 2015 to June 30, 2018. Primary outcomes ascertained through December 31, 2018 included in-and out-of-hospital mortality. Secondary outcomes included bleeding, amputation, stroke, and lower extremity revascularization. Multivariable regression models with adjustment for confounders were used to estimate risk. Subgroup analyses included patients treated with MCS and those who underwent coronary revascularization. RESULTS Among 71,690 patients, 5.9% (N = 4,259) had PAD. Mean age was 77.8 +/- 7.9 years, 58.7% were male, and 84.3% were White. Cumulative in-hospital mortality was 47.2%, with greater risk among those with PAD (56.3% vs 46.6% without PAD; adjusted OR: 1.50; 95% CI: 1.40-1.59). PAD patients also had greater risk of in-hospital amputation (1.6% vs 0.2%; adjusted OR: 7.0; 95% CI: 5.26-9.37) and out-of-hospital mortality (67.9% vs 40.7%; adjusted HR: 1.78; 95% CI: 1.67-1.90). MCS was less frequently utilized in PAD patients (21.5% vs 38.6% without PAD; P < 0.001) and was associated with higher mortality, need for lower extremity revascularization, and amputation risk. Findings were consistent in patients who underwent coronary revascularization. CONCLUSIONS Among patients presenting with AMI and CS, PAD was associated with worse limb outcomes and survival. In addition to lower MCS utilization rates, those with PAD who received MCS had increased mortality, lower extremity revascularization, and amputation rates. (C) 2022 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据